JP2024546497A5 - - Google Patents

Info

Publication number
JP2024546497A5
JP2024546497A5 JP2024535848A JP2024535848A JP2024546497A5 JP 2024546497 A5 JP2024546497 A5 JP 2024546497A5 JP 2024535848 A JP2024535848 A JP 2024535848A JP 2024535848 A JP2024535848 A JP 2024535848A JP 2024546497 A5 JP2024546497 A5 JP 2024546497A5
Authority
JP
Japan
Prior art keywords
antibody
drug conjugate
pharmaceutical composition
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024535848A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024546497A (ja
JP7796230B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/139637 external-priority patent/WO2023109953A1/zh
Publication of JP2024546497A publication Critical patent/JP2024546497A/ja
Publication of JP2024546497A5 publication Critical patent/JP2024546497A5/ja
Priority to JP2025271167A priority Critical patent/JP2026053502A/ja
Application granted granted Critical
Publication of JP7796230B2 publication Critical patent/JP7796230B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024535848A 2021-12-17 2022-12-16 Claudin18.2を標的とする抗体―薬物複合体 Active JP7796230B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025271167A JP2026053502A (ja) 2021-12-17 2025-12-22 Claudin18.2を標的とする抗体―薬物複合体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202111551337.8 2021-12-17
CN202111551337 2021-12-17
PCT/CN2022/139637 WO2023109953A1 (zh) 2021-12-17 2022-12-16 靶向Claudin18.2的抗体-药物偶联物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025271167A Division JP2026053502A (ja) 2021-12-17 2025-12-22 Claudin18.2を標的とする抗体―薬物複合体

Publications (3)

Publication Number Publication Date
JP2024546497A JP2024546497A (ja) 2024-12-24
JP2024546497A5 true JP2024546497A5 (cg-RX-API-DMAC7.html) 2025-11-11
JP7796230B2 JP7796230B2 (ja) 2026-01-08

Family

ID=86774867

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2024535848A Active JP7796230B2 (ja) 2021-12-17 2022-12-16 Claudin18.2を標的とする抗体―薬物複合体
JP2025271167A Pending JP2026053502A (ja) 2021-12-17 2025-12-22 Claudin18.2を標的とする抗体―薬物複合体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025271167A Pending JP2026053502A (ja) 2021-12-17 2025-12-22 Claudin18.2を標的とする抗体―薬物複合体

Country Status (9)

Country Link
US (2) US20250073347A1 (cg-RX-API-DMAC7.html)
EP (1) EP4450521A1 (cg-RX-API-DMAC7.html)
JP (2) JP7796230B2 (cg-RX-API-DMAC7.html)
KR (1) KR20240133715A (cg-RX-API-DMAC7.html)
CN (1) CN119173534A (cg-RX-API-DMAC7.html)
AU (1) AU2022416272A1 (cg-RX-API-DMAC7.html)
CA (1) CA3242970A1 (cg-RX-API-DMAC7.html)
TW (1) TWI869741B (cg-RX-API-DMAC7.html)
WO (1) WO2023109953A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022416272A1 (en) * 2021-12-17 2024-07-18 Fortvita Biologics (Singapore) Pte. Ltd. Antibody-drug conjugate targeting claudin18.2
EP4623936A1 (en) * 2022-11-22 2025-10-01 Keymed Biosciences (Chengdu) Co., Ltd. Fused ring compound, conjugate thereof and use thereof
CN119591708A (zh) * 2023-09-08 2025-03-11 成都临界点生物科技有限公司 抗Claudin18.2人源化单域抗体
WO2025077815A1 (zh) * 2023-10-11 2025-04-17 福佑泰生物制药(新加坡)公司 靶向Claudin18.2的抗体-药物偶联物联合治疗癌症的方法
TW202532100A (zh) * 2023-12-22 2025-08-16 大陸商信達生物製藥(蘇州)有限公司 靶向b7h3和egfr的雙特異性抗體-藥物偶聯物及其應用
TW202545991A (zh) * 2024-01-12 2025-12-01 大陸商信達生物製藥(蘇州)有限公司 抗cd28抗體及其用途
WO2026052046A1 (zh) * 2024-09-06 2026-03-12 荣昌生物制药(烟台)股份有限公司 抗Claudin18.2抗体药物偶联物用于治疗胃癌和/或胃食管结合部腺癌的用途
CN119345386B (zh) * 2024-10-25 2025-12-09 华润生物医药有限公司 靶向Claudin18.2的抗体药物耦联物及其用途
WO2026120140A1 (en) 2024-12-05 2026-06-11 Medizinische Universität Wien Hydroxy cinnamic acid derivatives
WO2026124417A1 (en) * 2024-12-09 2026-06-18 Lepu Biopharma Co., Ltd. Anti-cdh17 antibody-drug conjugates and uses thereof
CN121130103A (zh) * 2025-11-05 2025-12-16 上海以岭药业有限公司 靶向cldn 18.2的抗体药物偶联物及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9580511B2 (en) * 2013-03-11 2017-02-28 Genzyme Corporation Site-specific antibody-drug conjugation through glycoengineering
CN106589127A (zh) * 2015-10-16 2017-04-26 钜川生物医药 一种pcsk9抗体及其制备方法和应用
CA3177215C (en) * 2017-09-29 2026-06-09 Daiichi Sankyo Company, Limited Antibody-pyrrolobenzodiazepine derivative conjugate
EP3808376A4 (en) * 2018-06-17 2021-09-01 L&L Biopharma Co., Ltd. CLDN18.2 ANTIBODY, BISPECIFIC ANTIBODY, ADC AND CAR, AND APPLICATIONS THEREOF
AU2019414968A1 (en) * 2018-12-27 2021-08-12 Gigagen, Inc. Anti-PD-1 binding proteins and methods of use thereof
KR20210109520A (ko) * 2018-12-28 2021-09-06 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 항체 및 이의 용도
EP3950061A4 (en) * 2019-03-25 2022-11-16 Daiichi Sankyo Company, Limited ANTIBODY PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE
CN117731798A (zh) 2019-06-28 2024-03-22 泰州复旦张江药业有限公司 抗体偶联药物、其中间体、制备方法及应用
CA3147122A1 (en) * 2019-07-12 2021-01-21 Futuregen Biopharmaceutical (Beijing) Co., Ltd. Cldn18.2 antibody and use thereof
CN112707965A (zh) * 2019-09-30 2021-04-27 和铂医药(苏州)有限公司 靶向cldn18.2的抗体及其制备方法和应用
AU2020402006A1 (en) 2019-12-12 2022-07-07 Jiangsu Hengrui Medicine Co., Ltd. Anti-claudin antibody-drug conjugate and pharmaceutical use thereof
CA3178855A1 (en) * 2020-06-19 2021-12-23 Innovent Biologics (Suzhou) Co., Ltd. Anti-claudin18.2 antibody and use thereof
JP7904824B2 (ja) 2020-09-15 2026-08-13 シンアフィックス ビー.ブイ. 抗体-エクサテカンコンジュゲート
US20240293457A1 (en) * 2020-12-25 2024-09-05 Innovent Biologics (Suzhou) Co., Ltd. Claudin18.2 chimeric antigen receptor and use thereof
AU2022416272A1 (en) * 2021-12-17 2024-07-18 Fortvita Biologics (Singapore) Pte. Ltd. Antibody-drug conjugate targeting claudin18.2

Similar Documents

Publication Publication Date Title
JP2022191301A5 (cg-RX-API-DMAC7.html)
TWI865337B (zh) 抗體-藥物結合物之有效的製造方法
JP2019532056A5 (cg-RX-API-DMAC7.html)
JP2025111463A5 (cg-RX-API-DMAC7.html)
JP2024016177A5 (cg-RX-API-DMAC7.html)
JP2024109678A5 (cg-RX-API-DMAC7.html)
JP2021527640A5 (cg-RX-API-DMAC7.html)
JP2020509027A5 (cg-RX-API-DMAC7.html)
JP2025131696A5 (cg-RX-API-DMAC7.html)
JP2025183307A5 (cg-RX-API-DMAC7.html)
JP2024167313A5 (cg-RX-API-DMAC7.html)
JP2020518598A5 (cg-RX-API-DMAC7.html)
JP2019536740A5 (cg-RX-API-DMAC7.html)
JP2023535598A5 (cg-RX-API-DMAC7.html)
JP2019107018A5 (cg-RX-API-DMAC7.html)
JP2023500875A5 (cg-RX-API-DMAC7.html)
RU2018119296A (ru) Конъюгаты антитела, содержащие агонисты толл-подобного рецептора
RU2022111211A (ru) Конъюгаты анти-cd71 активируемое антитело - лекарственное средство и способы их применения
JP2021528423A5 (cg-RX-API-DMAC7.html)
JP2023547323A5 (cg-RX-API-DMAC7.html)
JP2022523442A5 (cg-RX-API-DMAC7.html)
JP2025038088A5 (cg-RX-API-DMAC7.html)
JP2024521921A5 (cg-RX-API-DMAC7.html)
JP2023519776A5 (cg-RX-API-DMAC7.html)
JP2024540148A5 (cg-RX-API-DMAC7.html)